Loxo Oncology Announces Publication of Larotrectinib Clinical Data in The New England Journal of Medicine

STAMFORD, Conn., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, and Bayer AG, Germany, today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials